Eli Lilly: Treatment may be effective against virus
Eli Lilly and Company Vice President of Immunology Dr. Ajay Nirula announced on Wednesday that the company’s COVID-19 antibody treatment candidate bamlanivimab, or LY-CoV555, “may be effective in treating COVID-19 by reducing viral load, symptoms and the risk of hospitalization in outpatients,” according to data from the Phase 2 study published by the New England Journal of Medicine.
The data has shown that “one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11” and that “the percentage of patients who had a Covid-19-related hospitalization or visit to an emergency department was 1.6% in the LY-CoV555 group and 6.3% in the placebo group.” The company said that the results have been submitted to the US Food and Drug Administration with the purpose of seeking an emergency use authorization.
Eli Lilly’s shares rose by 0.91% in after-hours trading following the release of the report.
Get involved!
Comments